ClinicalTrials.gg
Not yet recruitingNCT07291622Updated Dec 24, 2025

Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients

An interventional study of SYNC-NIV in Ventilator Associated Events, Asynchrony, Patient-Ventilator and Intensive Care (ICU), sponsored by Shahid Beheshti University of Medical Sciences. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Shahid Beheshti University of Medical Sciences · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this clinical trial is to find out whether a synchrony-optimized education program for non-invasive ventilation (NIV) can help ICU patients use their ventilator more effectively and improve their comfort, symptoms, and psychological well-being.

Researchers want to answer these main questions:

Can a structured two-session NIV education program help patients use their ventilator more regularly and for longer periods?

Does this type of training reduce anxiety, depression, and respiratory symptoms?

Can synchrony training improve patients' comfort and reduce NIV-related problems such as mask leaks or sleep disturbances?

Is this program more effective than the routine ICU education normally provided?

What Will Happen in the Study

Adults (18+) who are receiving NIV in the ICU will participate in this study.

Participants will be randomly assigned to one of two groups:

Intervention Group: Will receive the SYNC-NIV education program, consisting of:

One hands-on session (20-40 minutes) teaching patients how to synchronize their breathing with the ventilator

One supplementary session (45-60 minutes) covering mask management, preventing complications, reducing leaks, breathing exercises, equipment care, and alarm handling

An educational booklet for continued support

Control Group: Will receive the standard ICU education normally provided about the ICU environment, general care, communication, and monitoring.

All participants will be evaluated at three times:

before the intervention, the day after the program ends, and one week later.

02

Conditions studied

  • Ventilator Associated Events
  • Asynchrony, Patient-Ventilator
  • Intensive Care (ICU)
  • Noninvasive Ventilation

Keywords

  • Non-Invasive Ventilation
  • Patient-Ventilator Synchrony
  • Intensive Care Unit (ICU)
  • Anxiety and Depression
  • Randomized Clinical Trial
  • Patient Comfort
03

In context

Patient-Ventilator Asynchrony

24 studies on the registry are indexed under Patient-Ventilator Asynchrony; 11 are open to participants now.

This study's planned enrollment of 92 is above the median of 38 across 11 interventional studies indexed under Patient-Ventilator Asynchrony.

Browse Patient-Ventilator Asynchrony studies →

Lead sponsor

Shahid Beheshti University of Medical Sciences is the lead sponsor of 229 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients over 18 years of age
  • Admitted to the ICU for at least 24 hours
  • Anticipated to be hospitalized for more than one week
  • Receiving NIV treatment for any underlying condition
  • Capable of learning
  • Proficient in the Persian language

Exclusion criteria

Exclusion Criteria:

  • Patients with Richmond Agitation-Sedation Scale (RASS) scores of +4 or -5
  • Patients with cognitive disorders
  • Patients with neurological disorders
  • Patients with anxiety disorders
  • Patients whose condition deteriorates, making continued cooperation impossible
  • Patients unable to participate in educational sessions
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    SYNC-NIV

    The intervention will consist of a structured two-session synchrony-optimized NIV education program designed to improve patient-ventilator interaction and reduce NIV-related complications. In the first 20-40-minute session, patients will be taught the ventilator's inspiratory and expiratory cycles and will practice synchronizing their breathing with the device through guided diaphragmatic exercises and real-time feedback until they demonstrate stable synchrony. The second 45-60-minute session, delivered 18-24 hours later, will provide supplementary training on proper mask selection and fixation, prevention of common NIV complications, leak reduction techniques, equipment maintenance, advanced breathing exercises, and basic ventilator monitoring and alarm management. An educational booklet summarizing all essential topics will be provided to support ongoing adherence and self-management.

    Other: SYNC-NIV

  • No intervention
    Control Group

    Standard care will include regular education on the ICU environment, basic intensive care processes, the use of monitoring devices, ICU rules, effective communication with critically ill patients, and basic principles of patient care.

Interventions

  • OtherSYNC-NIV

    The intervention will include two educational sessions to improve patient-ventilator synchrony and NIV management. The first session will teach patients about the ventilator's breathing cycles and train them to coordinate their breathing using visual aids and hands-on practice with real-time feedback. Competency will be assessed by their ability to maintain synchrony with minimal mask leak. The second session, held 18-24 hours later, will cover mask fitting, prevention of common complications, leak reduction, equipment care, advanced breathing exercises, and basic ventilator alarm management. Communication and relaxation techniques will also be taught, and patients will receive a booklet summarizing the key information.

06

What researchers measure

Primary outcomes

  1. NIV Usage

    Adherence data, including daily NIV usage, will be retrieved from the NIV machine. Adherence will be defined as more than 4 hours of nighttime use for more than 70% of days until study completion or a mean daily use of more than 5 hours.

    Time frame: Baseline, the day after SYNC-NIV program completion, and 1 week after program completion

Secondary outcomes

  1. Anxiety and Depression

    Levels of anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-report instrument divided into two subscales: anxiety (HADS-A) and depression (HADS-D), each comprising seven items. Participants will rate each item on a 4-point scale (0-3), yielding subscale scores ranging from 0 to 21. Scores for both subscales will be interpreted as follows: 0-7 indicating no symptoms, 8-10 mild, 11-14 moderate, and 15-21 severe. The internal consistency of the anxiety subscale (HADS-A) and depression subscale (HADS-D) will have been demonstrated with Cronbach's alpha coefficients of 0.820 and 0.807, respectively. The Persian version of the HADS will have shown good reliability and validity in clinical populations. Montazeri et al. (2003) will have found it acceptable by 99% of patients, with Cronbach's alpha of 0.78 for anxiety and 0.86 for depression subscales.

    Time frame: Baseline, the day after SYNC-NIV program completion, and 1 week after program completion

  2. Respiratory Symptoms, Sleep Quality, and NIV-Associated Adverse Events

    Respiratory Symptoms, Sleep Quality, and NIV-Associated Adverse Events The S3-NIV Questionnaire will be a self-administered tool that includes 11 questions, all scored by patients on a 5-point Likert scale that ranges from 0 to 4 (0 = always true; 1 = mostly true; 2 = sometimes true; 3 = mostly untrue; 4 = completely untrue), based on their experiences over the previous four weeks. To calculate the overall score, the average of all completed items will be multiplied by 2.5. A score of zero will reflect the highest degree of disease impact, whereas a score of ten will reflect the lowest. Two subscale scores may also be derived: the "Respiratory Symptoms" sub score will be computed by averaging responses to items 1, 4, 5, 6, and 7 and multiplying by 2.5, while the "Sleep \& Side Effects" sub score will be based on the average of items 2, 3, 8, 9, 10, and 11, also multiplied by 2.5.

    Time frame: Baseline, the day after SYNC-NIV program completion, and 1 week after program completion

  3. Comfort

    To evaluate participants' comfort levels, the Visual Analog Scale (VAS) will be employed. The VAS will be a widely used, reliable, and sensitive instrument for assessing subjective experiences such as comfort (6). It typically will consist of a 10-centimeter horizontal line anchored by two extremes, for example, "no discomfort" on the left end (score 0) and "worst possible discomfort" on the right end (score 10). Participants will mark a point along the line that best represents their perceived level of comfort. The simplicity, sensitivity, and ease of administration of the VAS will make it a preferred tool in both clinical and research settings for quantifying subjective states.

    Time frame: Baseline, the day after SYNC-NIV program completion, and 1 week after program completion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2025, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 18, 2025
StartEst.
Dec 19, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jan 10, 2026
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07291622
Responsible party
Sogand Sarmadi (Principal Investigator, Shahid Beheshti University of Medical Sciences) — Principal investigator
First posted
Dec 18, 2025
Start date
Dec 19, 2025 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
Jan 10, 2026 (estimated)
Last update
Dec 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion